Logo

Grit Biotechnology Reports the US FDA’s IND Approval of GT201 for Treating Advanced Solid Tumors

Share this

Grit Biotechnology Reports the US FDA’s IND Approval of GT201 for Treating Advanced Solid Tumors

Shots:

  • The US FDA has granted clearance to the company’s IND application for GT201 for treating advanced solid tumors. It received IND approval across China in Jul 2023
  • GT201 is a genetically engineered TIL product developed using StemTexp and StaViral platforms. It enhances T cell survival through membrane-bound cytokine complex expression, improving tumor-killing efficacy and long-term survival
  • Grit's another program, GT101 (non-gene-engineered TIL program), is under pivotal P-II clinical evaluation with its BLA planned in 2025

Ref: Grit Biotechnology | Image: Grit Biotechnology

Related News:- Zymeworks Reports the US FDA’s IND Clearance of ZW191 for Treating Solid Tumors

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions